Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on Biogen’s net sales of Tecfidera® or other DMF products for multiple sclerosis outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the ‘355 Patent Opposition Proceeding, including any appeal thereto.

Biotechnology

Forward Pharma

Forward Pharma's headquarters in København, Denmark

Grant Hellier Lawrence

Torsten Goesch

Duncan Moore

Florian Schönharting

Jakob Mosegaard Larsen

Forward Pharma's Leadership Team includes Claus Bo Svendsen.

About

People

Jobs